DK3848038T3 - 11-Hydroxyl-6substituerede-derivater af galdesyrer og aminosyrerkonjugater heraf som farnesoid X receptor modulerer. - Google Patents

11-Hydroxyl-6substituerede-derivater af galdesyrer og aminosyrerkonjugater heraf som farnesoid X receptor modulerer. Download PDF

Info

Publication number: DK3848038T3
Authority: DK; Denmark
Prior art keywords: farnesoid; hydroxyl; amino acid; bile acids; substituted derivatives
Prior art date: 2013-05-14

Application number

DK20211780.0T

Other languages

English (en)

Inventor

Roberto Pellicciari

Original Assignee

Intercept Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-05-14

Filing date

2014-05-14

Publication date

2023-02-06

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50721801&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3848038(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-05-14 Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc

2023-02-06 Application granted granted Critical

2023-02-06 Publication of DK3848038T3 publication Critical patent/DK3848038T3/da

Links

102100038495 Bile acid receptor Human genes 0.000 title 1
101000603876 Homo sapiens Bile acid receptor Proteins 0.000 title 1
150000001413 amino acids Chemical class 0.000 title 1
239000003613 bile acid Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
- C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

DK20211780.0T 2013-05-14 2014-05-14 11-Hydroxyl-6substituerede-derivater af galdesyrer og aminosyrerkonjugater heraf som farnesoid X receptor modulerer. DK3848038T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361823169P	2013-05-14	2013-05-14
EP18163622.6A EP3360881B1 (en)	2013-05-14	2014-05-14	11-hydroxyl-6-substituted-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators

Publications (1)

Publication Number	Publication Date
DK3848038T3 true DK3848038T3 (da)	2023-02-06

Family

ID=50721801

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
DK18163622.6T DK3360881T3 (da)	2013-05-14	2014-05-14	11-hydroxy-6-substituerede derivater af galdesyrer og aminosyrekonjagater deraf som farnesoid X receptormodulatorer
DK14723820.8T DK2997035T3 (da)	2013-05-14	2014-05-14	11-hydroxy-6-substituerede derivater af galdesyrer og aminosyrekonjugater deraf som farnesoid x-receptormodulatorer
DK20211780.0T DK3848038T3 (da)	2013-05-14	2014-05-14	11-Hydroxyl-6substituerede-derivater af galdesyrer og aminosyrerkonjugater heraf som farnesoid X receptor modulerer.
DK18163623.4T DK3360882T3 (da)	2013-05-14	2014-05-14	11-hydroxyl-6-substituterede derivater af galsyre og aminosyrekonjugater deraf som farnesoid x receptormodulatorer

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
DK18163622.6T DK3360881T3 (da)	2013-05-14	2014-05-14	11-hydroxy-6-substituerede derivater af galdesyrer og aminosyrekonjagater deraf som farnesoid X receptormodulatorer
DK14723820.8T DK2997035T3 (da)	2013-05-14	2014-05-14	11-hydroxy-6-substituerede derivater af galdesyrer og aminosyrekonjugater deraf som farnesoid x-receptormodulatorer

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK18163623.4T DK3360882T3 (da)	2013-05-14	2014-05-14	11-hydroxyl-6-substituterede derivater af galsyre og aminosyrekonjugater deraf som farnesoid x receptormodulatorer

Country Status (38)

Country	Link
US (7)	US9611289B2 (da)
EP (4)	EP3360881B1 (da)
JP (2)	JP6326131B2 (da)
KR (1)	KR102229952B1 (da)
CN (2)	CN105377870B (da)
AU (1)	AU2014267324B2 (da)
BR (1)	BR112015028399B1 (da)
CA (1)	CA2912139C (da)
CL (2)	CL2015003344A1 (da)
CR (1)	CR20150643A (da)
CY (1)	CY1122614T1 (da)
DK (4)	DK3360881T3 (da)
EA (1)	EA030152B1 (da)
ES (4)	ES2936638T3 (da)
GT (1)	GT201500324A (da)
HK (2)	HK1253326A1 (da)
HR (1)	HRP20180931T1 (da)
HU (1)	HUE037996T2 (da)
IL (2)	IL242555B (da)
LT (1)	LT2997035T (da)
MA (1)	MA38647B1 (da)
ME (1)	ME03082B (da)
MX (1)	MX352065B (da)
MY (1)	MY187886A (da)
NI (1)	NI201500160A (da)
PE (1)	PE20160665A1 (da)
PH (1)	PH12015502576B1 (da)
PL (3)	PL2997035T3 (da)
PT (3)	PT3360882T (da)
RS (1)	RS57372B1 (da)
SA (1)	SA515370140B1 (da)
SG (1)	SG11201509352XA (da)
SI (3)	SI3360882T1 (da)
SM (1)	SMT201800326T1 (da)
TN (1)	TN2015000497A1 (da)
TR (1)	TR201809041T4 (da)
UA (1)	UA118673C2 (da)
WO (1)	WO2014184271A1 (da)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2440680C (en)	2001-03-12	2010-06-01	Roberto Pellicciari	Steroids as agonists for fxr
EP2545964A1 (en)	2011-07-13	2013-01-16	Phenex Pharmaceuticals AG	Novel FXR (NR1H4) binding and activity modulating compounds
PL2997035T3 (pl)	2013-05-14	2018-10-31	Intercept Pharmaceuticals, Inc.	11-hydroksy-6-podstawione pochodne kwasów żółciowych i ich koniugaty aminokwasowe jako modulatory receptorów farnezoidu x
US10301268B2 (en)	2014-03-13	2019-05-28	The Salk Institute For Biological Studies	Analogs of fexaramine and methods of making and using
US10077268B2 (en)	2014-03-13	2018-09-18	Salk Institute For Biological Studies	FXR agonists and methods for making and using
FI3626725T3 (fi)	2014-05-29	2023-03-16	Bar Pharmaceuticals S R L	Kolaanijohdannaisia käytettäväksi FXR:n ja TGR5:n/GPBAR1:n välittämien sairauksien hoidossa ja/tai ennaltaehkäisyssä
AU2015343025A1 (en)	2014-11-06	2017-06-08	Enanta Pharmaceuticals, Inc.	Bile acid analogs an FXR/TGR5 agonists and methods of use thereof
JP6735748B2 (ja)	2014-11-19	2020-08-05	エヌゼットピーユーケーリミテッド	ステロイドＦＸＲモジュレーター製造のための中間体としての６α−アルキル−３，７−ジオン−ステロイド
JP6698085B2 (ja)	2014-11-19	2020-05-27	エヌゼットピーユーケーリミテッド	ステロイドＦＸＲモジュレーター製造のための中間体としての６α−アルキル−６，７−ジオン−ステロイド
CA2968301C (en)	2014-11-19	2023-05-16	NZP UK Limited	5.beta.-6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal fxr modulators
KR102526631B1 (ko)	2014-11-19	2023-04-27	엔제트피 유케이 리미티드	스테로이드 fxr 조절인자를 제조하기 위한 중간체로서의 6-알킬-7-하이드록시-4-엔-3-온 스테로이드
WO2016086115A1 (en)	2014-11-26	2016-06-02	Enanta Pharmaceuticals, Inc.	Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof
MX2017006833A (es)	2014-11-26	2018-02-13	Enanta Pharm Inc	Análogos de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos.
US10208081B2 (en)	2014-11-26	2019-02-19	Enanta Pharmaceuticals, Inc.	Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
MA41094A (fr) *	2014-12-02	2017-10-10	Lilly Co Eli	Procédés de traitement de troubles rénaux
CN105348365A (zh) *	2014-12-03	2016-02-24	四川百利药业有限责任公司	一种胆酸衍生物及其制备方法、药物组合物和用途
CN104523703A (zh) *	2014-12-24	2015-04-22	聂飚	一种游离脂肪酸转运蛋白小分子抑制物的应用
US11311557B2 (en) *	2015-02-06	2022-04-26	Intercept Pharmaceuticals, Inc.	Pharmaceutical compositions for combination therapy
AU2016219266A1 (en)	2015-02-11	2017-08-10	Enanta Pharmaceuticals, Inc.	Bile acid analogs as FXR/TGR5 agonists and methods of use thereof
SG11201707328SA (en) *	2015-03-09	2017-10-30	Intercept Pharmaceuticals Inc	Methods for modulating bone density
US11072630B2 (en)	2015-03-10	2021-07-27	Metselex, Inc.	Fluorinated and alkylated bile acids
AU2016233579A1 (en) *	2015-03-13	2017-10-12	Salk Institute For Biological Studies	Treating latent autoimmune diabetes of adults with farnesoid X receptor agonists to activate intestinal receptors
RS62110B1 (sr)	2015-03-31	2021-08-31	Enanta Pharm Inc	Derivati žučnih kiselina kao agonisti fxr/tgr5 i postupci njihove upotrebe
BR112017021311A2 (pt) *	2015-04-07	2018-06-26	Intercept Pharmaceuticals Inc	composições farmacêuticas para terapia de combinação
WO2016168553A1 (en) *	2015-04-17	2016-10-20	Concert Pharmaceuticals, Inc.	Deuterated obeticholic acid
PE20180690A1 (es)	2015-04-27	2018-04-23	Intercept Pharmaceuticals Inc	Composiciones de acido obeticolico y metodos de uso
CN106478759A (zh) *	2015-08-31	2017-03-08	陕西合成药业股份有限公司	奥贝胆酸衍生物及其制备方法和用途
WO2017053428A1 (en)	2015-09-21	2017-03-30	Intercept Pharmaceuticals, Inc.	Methods of promoting hepatic regeneration
IL258359B2 (en) *	2015-10-07	2023-11-01	Intercept Pharmaceuticals Inc	Paranoid X receptor modulators.
SG11201806348PA (en) *	2016-01-28	2018-08-30	Chia Tai Tianqing Pharmaceutical Group Co Ltd	Steroid derivative fxr agonist
WO2017147159A1 (en)	2016-02-23	2017-08-31	Enanta Pharmaceuticals, Inc.	Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
WO2017147174A1 (en) *	2016-02-23	2017-08-31	Enanta Pharmaceuticals, Inc.	Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
US10323060B2 (en)	2016-02-23	2019-06-18	Enanta Pharmaceuticals, Inc.	Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof
ES2874682T3 (es) *	2016-03-11	2021-11-05	Intercept Pharmaceuticals Inc	Derivados de 3-desoxi y composiciones farmacéuticas de los mismos
WO2017180577A1 (en) *	2016-04-13	2017-10-19	Intercept Pharmaceuticals, Inc.	Methods of treating cancer
GB201608777D0 (en)	2016-05-18	2016-06-29	Dextra Lab Ltd	Compounds
AU2017284160B2 (en)	2016-06-13	2019-12-19	Gilead Sciences, Inc.	FXR (NR1H4) modulating compounds
CA2968836A1 (en)	2016-06-13	2017-12-13	Gilead Sciences, Inc.	Fxr (nr1h4) modulating compounds
KR102499441B1 (ko)	2016-11-29	2023-02-13	이난타 파마슈티칼스, 인코포레이티드	술포닐우레아 담즙산 유도체의 제조 방법
US10472386B2 (en)	2017-02-14	2019-11-12	Enanta Pharmaceuticals, Inc.	Bile acid derivatives as FXR agonists and methods of use thereof
ES2959842T3 (es)	2017-02-21	2024-02-28	Genfit	Combinación de un agonista de PPAR con un agonista de FXR
AU2018225255A1 (en) *	2017-02-23	2019-09-05	Intercept Pharmaceuticals, Inc	Pharmaceutical compositions of a bile acid derivative and microbiome and uses thereof
KR102743630B1 (ko)	2017-03-28	2024-12-18	길리애드 사이언시즈, 인코포레이티드	간 질환을 치료하기 위한 치료 조합물
BR112019020780A2 (pt)	2017-04-07	2020-04-28	Enanta Pharm Inc	processo para preparação de derivados de ácido biliar de carbamato de sulfonila
WO2018226724A1 (en) *	2017-06-05	2018-12-13	Intercept Pharmaceuticals, Inc.	Treatment and prevention of diabetic eye diseases with a bile acid derivatives
CA3067219A1 (en) *	2017-06-23	2018-12-27	Intercept Pharmaceuticals, Inc.	Methods and intermediates for the preparation of bile acid derivatives
KR20200031145A (ko)	2017-07-24	2020-03-23	인터셉트 파마슈티컬즈, 인크.	동위원소 표지된 담즙산 유도체
GB201812382D0 (en)	2018-07-30	2018-09-12	Nzp Uk Ltd	Compounds
CN109182451B (zh) *	2018-08-21	2021-06-11	四川大学	细胞色素cyp3a7酶的新型特异性探针反应及其应用
SG11202107434PA (en)	2019-01-15	2021-08-30	Gilead Sciences Inc	Fxr (nr1h4) modulating compounds
CA3129949C (en)	2019-02-19	2024-04-30	Gilead Sciences, Inc.	Solid forms of fxr agonists
KR20220016146A (ko)	2019-05-30	2022-02-08	인터셉트 파마슈티컬즈, 인크.	담즙정체성 간 질환의 치료에서 사용하기 위한 fxr 효능제 및 피브레이트를 포함하는 제약 조성물
JP7597787B2 (ja)	2019-07-18	2024-12-10	ウエヌイグレックオ・ファーマ	インターフェロンの有害作用を減少させる方法
CN110540955B (zh) *	2019-08-28	2021-09-17	北京协同创新研究院	一种提高分化细胞中nrob2基因表达量的方法
ES3014367T3 (en)	2020-01-15	2025-04-22	Inst Nat Sante Rech Med	Use of fxr agonists for treating an infection by hepatitis d virus
MX2023008365A (es)	2021-01-14	2023-10-04	Enyo Pharma	Efecto sinérgico de un agonista de fxr e ifn para el tratamiento de infección por hbv.
US20240216364A1 (en)	2021-04-28	2024-07-04	Enyo Pharma	Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment
WO2022233398A1 (en) *	2021-05-04	2022-11-10	Kostner Pharma Gmbh	COMPOUNDS FOR REDUCING LIPOPROTEIN(a)
WO2023288123A1 (en)	2021-07-16	2023-01-19	Interecept Pharmaceuticals, Inc.	Methods and intermediates for the preparation of 3.alpha.,7.alpha.,11.beta.-trihydroxy-6.alpha.-ethyl-5.beta.-cholan-24-oic acid

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2080775A (en) *	1934-08-22	1937-05-18	Celanese Corp	Shedding mechanism for circular looms
US2802775A (en) *	1953-05-29	1957-08-13	Merck & Co Inc	11 alpha-hydroxylation of steroids by aspergillus ochraceus
JPS59205396A (ja) *	1983-05-09	1984-11-20	Kuraray Co Ltd	１１β−ヒドロキシプレグナ−４−エン−３−オン−２０−カルブアルデヒド及びその製造法
JP2002532729A (ja)	1998-12-23	2002-10-02	グラクソグループリミテッド	核内受容体のリガンドのアッセイ
ITMI20021532A1 (it) *	2002-07-12	2004-01-12	Roberto Pellicciari	Composti chimici
EP1568706A1 (en) *	2004-02-26	2005-08-31	Intercept Pharmaceuticals, Inc.	Novel steroid agonist for FXR
US9498484B2 (en) *	2004-03-12	2016-11-22	Intercept Pharmaceuticals, Inc.	Treatment of fibrosis using FXR ligands
SI2040713T1 (sl) *	2006-06-27	2014-11-28	Intercept Pharmaceuticals, Inc.	Derivati žolčne kisline kot FXR ligandi za preprečevanje ali zdravljenje bolezni ali stanj, posredovanih s FXR
PL2997035T3 (pl)	2013-05-14	2018-10-31	Intercept Pharmaceuticals, Inc.	11-hydroksy-6-podstawione pochodne kwasów żółciowych i ich koniugaty aminokwasowe jako modulatory receptorów farnezoidu x

2014
- 2014-05-14 PL PL14723820T patent/PL2997035T3/pl unknown
- 2014-05-14 PT PT181636234T patent/PT3360882T/pt unknown
- 2014-05-14 EP EP18163622.6A patent/EP3360881B1/en active Active
- 2014-05-14 HU HUE14723820A patent/HUE037996T2/hu unknown
- 2014-05-14 ES ES20211780T patent/ES2936638T3/es active Active
- 2014-05-14 PT PT181636226T patent/PT3360881T/pt unknown
- 2014-05-14 UA UAA201511098A patent/UA118673C2/uk unknown
- 2014-05-14 MX MX2015015730A patent/MX352065B/es active IP Right Grant
- 2014-05-14 BR BR112015028399-3A patent/BR112015028399B1/pt active IP Right Grant
- 2014-05-14 RS RS20180690A patent/RS57372B1/sr unknown
- 2014-05-14 AU AU2014267324A patent/AU2014267324B2/en active Active
- 2014-05-14 PT PT147238208T patent/PT2997035T/pt unknown
- 2014-05-14 DK DK18163622.6T patent/DK3360881T3/da active
- 2014-05-14 SM SM20180326T patent/SMT201800326T1/it unknown
- 2014-05-14 TR TR2018/09041T patent/TR201809041T4/tr unknown
- 2014-05-14 ES ES14723820.8T patent/ES2671427T3/es active Active
- 2014-05-14 EP EP14723820.8A patent/EP2997035B8/en active Active
- 2014-05-14 DK DK14723820.8T patent/DK2997035T3/da active
- 2014-05-14 ES ES18163623T patent/ES2843737T3/es active Active
- 2014-05-14 TN TN2015000497A patent/TN2015000497A1/en unknown
- 2014-05-14 US US14/120,366 patent/US9611289B2/en active Active
- 2014-05-14 SG SG11201509352XA patent/SG11201509352XA/en unknown
- 2014-05-14 DK DK20211780.0T patent/DK3848038T3/da active
- 2014-05-14 MY MYPI2015002734A patent/MY187886A/en unknown
- 2014-05-14 KR KR1020157034951A patent/KR102229952B1/ko active Active
- 2014-05-14 JP JP2016513357A patent/JP6326131B2/ja active Active
- 2014-05-14 SI SI201431741T patent/SI3360882T1/sl unknown
- 2014-05-14 MA MA38647A patent/MA38647B1/fr unknown
- 2014-05-14 EP EP20211780.0A patent/EP3848038B1/en active Active
- 2014-05-14 DK DK18163623.4T patent/DK3360882T3/da active
- 2014-05-14 ME MEP-2018-159A patent/ME03082B/me unknown
- 2014-05-14 EP EP18163623.4A patent/EP3360882B1/en active Active
- 2014-05-14 CA CA2912139A patent/CA2912139C/en active Active
- 2014-05-14 LT LTEP14723820.8T patent/LT2997035T/lt unknown
- 2014-05-14 ES ES18163622T patent/ES2847002T3/es active Active
- 2014-05-14 PL PL18163622T patent/PL3360881T3/pl unknown
- 2014-05-14 PE PE2015002397A patent/PE20160665A1/es unknown
- 2014-05-14 SI SI201431742T patent/SI3360881T1/sl unknown
- 2014-05-14 SI SI201430701T patent/SI2997035T1/sl unknown
- 2014-05-14 EA EA201592055A patent/EA030152B1/ru unknown
- 2014-05-14 WO PCT/EP2014/059896 patent/WO2014184271A1/en active Application Filing
- 2014-05-14 PL PL18163623T patent/PL3360882T3/pl unknown
- 2014-05-14 CN CN201480036949.5A patent/CN105377870B/zh active Active
- 2014-05-14 CN CN201810162562.4A patent/CN108245523B/zh not_active Expired - Fee Related
2015
- 2015-11-12 IL IL242555A patent/IL242555B/en active IP Right Grant
- 2015-11-12 SA SA515370140A patent/SA515370140B1/ar unknown
- 2015-11-13 NI NI201500160A patent/NI201500160A/es unknown
- 2015-11-13 GT GT201500324A patent/GT201500324A/es unknown
- 2015-11-13 CL CL2015003344A patent/CL2015003344A1/es unknown
- 2015-11-13 PH PH12015502576A patent/PH12015502576B1/en unknown
- 2015-12-07 CR CR20150643A patent/CR20150643A/es unknown
2016
- 2016-07-15 CL CL2016001809A patent/CL2016001809A1/es unknown
- 2016-08-15 HK HK18112619.6A patent/HK1253326A1/zh unknown
- 2016-08-15 HK HK16109719.3A patent/HK1221471A1/zh unknown
2017
- 2017-02-16 US US15/434,685 patent/US20170216316A1/en not_active Abandoned
2018
- 2018-04-13 JP JP2018077654A patent/JP2018127481A/ja not_active Withdrawn
- 2018-06-01 CY CY20181100583T patent/CY1122614T1/el unknown
- 2018-06-15 HR HRP20180931TT patent/HRP20180931T1/hr unknown
- 2018-09-06 US US16/124,139 patent/US10532061B2/en active Active
2019
- 2019-11-26 US US16/695,528 patent/US11000532B2/en active Active
2020
- 2020-02-17 IL IL272718A patent/IL272718B/en active IP Right Grant
2021
- 2021-04-13 US US17/228,819 patent/US20210228599A1/en not_active Abandoned
2023
- 2023-04-03 US US18/295,091 patent/US20230233581A1/en not_active Abandoned
2024
- 2024-08-12 US US18/800,808 patent/US20240398834A1/en active Pending

Also Published As

Publication number	Publication date
MA38647B1 (fr)	2019-05-31
IL272718B (en)	2020-11-30
MY187886A (en)	2021-10-26
RS57372B1 (sr)	2018-08-31
HK1253326A1 (zh)	2019-06-14
DK3360882T3 (da)	2021-03-08
IL272718A (en)	2020-04-30
CL2015003344A1 (es)	2016-07-15
TR201809041T4 (tr)	2018-07-23
ES2671427T3 (es)	2018-06-06
CN105377870B (zh)	2018-04-03
ME03082B (me)	2019-01-20
EP2997035B8 (en)	2018-05-23
PL3360882T3 (pl)	2021-10-25
JP2016518429A (ja)	2016-06-23
EP3360881A1 (en)	2018-08-15
CA2912139A1 (en)	2014-11-20
EP2997035A1 (en)	2016-03-23
EP3360882A1 (en)	2018-08-15
EP3848038B1 (en)	2022-11-09
EA201592055A1 (ru)	2016-11-30
SI2997035T1 (sl)	2018-10-30
JP2018127481A (ja)	2018-08-16
US9611289B2 (en)	2017-04-04
BR112015028399A2 (pt)	2017-07-25
US20140371190A1 (en)	2014-12-18
AU2014267324B2 (en)	2017-11-02
ES2843737T3 (es)	2021-07-20
CY1122614T1 (el)	2020-07-31
CR20150643A (es)	2016-06-01
ES2847002T3 (es)	2021-07-30
SMT201800326T1 (it)	2018-07-17
US20170216316A1 (en)	2017-08-03
KR102229952B1 (ko)	2021-03-22
SI3360882T1 (sl)	2021-06-30
EP3848038A1 (en)	2021-07-14
GT201500324A (es)	2017-09-28
PH12015502576A1 (en)	2016-02-29
DK3360881T3 (da)	2021-03-15
US20240398834A1 (en)	2024-12-05
EP3360882B1 (en)	2020-12-09
EP2997035B1 (en)	2018-03-28
UA118673C2 (uk)	2019-02-25
HK1221471A1 (zh)	2017-06-02
LT2997035T (lt)	2018-08-10
CA2912139C (en)	2021-04-20
CN108245523A (zh)	2018-07-06
NI201500160A (es)	2016-01-04
HRP20180931T1 (hr)	2018-10-05
PL3360881T3 (pl)	2021-11-15
DK2997035T3 (da)	2018-07-02
US20230233581A1 (en)	2023-07-27
BR112015028399B1 (pt)	2021-11-16
CN108245523B (zh)	2021-03-26
PL2997035T3 (pl)	2018-10-31
JP6326131B2 (ja)	2018-05-16
SI3360881T1 (sl)	2021-06-30
PT3360882T (pt)	2021-02-12
US20200297739A1 (en)	2020-09-24
US11000532B2 (en)	2021-05-11
US20190209586A1 (en)	2019-07-11
PT2997035T (pt)	2018-07-18
EA030152B1 (ru)	2018-06-29
IL242555A0 (en)	2016-02-01
HUE037996T2 (hu)	2018-09-28
CN105377870A (zh)	2016-03-02
EP3360881B1 (en)	2020-12-09
TN2015000497A1 (en)	2017-04-06
CL2016001809A1 (es)	2017-01-27
IL242555B (en)	2020-04-30
SA515370140B1 (ar)	2017-04-11
NZ714082A (en)	2021-02-26
ES2936638T3 (es)	2023-03-21
SG11201509352XA (en)	2015-12-30
PE20160665A1 (es)	2016-08-07
PT3360881T (pt)	2021-02-19
MX352065B (es)	2017-11-08
PH12015502576B1 (en)	2018-09-12
US20210228599A1 (en)	2021-07-29
AU2014267324A1 (en)	2015-11-26
WO2014184271A1 (en)	2014-11-20
US10532061B2 (en)	2020-01-14
KR20160007586A (ko)	2016-01-20

Publication	Publication Date	Title
DK3848038T3 (da)	2023-02-06	11-Hydroxyl-6substituerede-derivater af galdesyrer og aminosyrerkonjugater heraf som farnesoid X receptor modulerer.
DK3434687T3 (da)	2021-06-07	Hidtil ukendte oxyntomodulinderivater og farmaceutisk præparat til behandling af fedme omfattende samme
DK2892912T3 (da)	2019-06-24	C17-alkandiyl og alkenediylderivater af oleanolsyre og fremgangsmåder til anvendelse deraf
DK3008168T3 (da)	2020-05-04	Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf
DK2930268T3 (da)	2021-03-01	Ekspansionsfuge
DK2932980T3 (da)	2021-07-19	Multivalent pneumokok-polysaccharid-proteinkonjugatsammensætning
DK3384902T3 (da)	2021-01-18	Fremgangsmåder, sammensætninger og indretninger til opfyldelse af diætmæssige behov for fedtsyre
DK2922955T3 (da)	2019-05-13	Sammensætninger og fremgangsmåder til modulering af FGFR3-ekspression
DK3060200T3 (da)	2021-07-12	Tyrosinderivater og sammensætninger dermed
DK2745849T3 (da)	2022-10-31	Polydeoxyribonukleotidsammensætning og anvendelser deraf
DK2985284T3 (da)	2022-02-07	Dicarboxylsyre bisamid derivater, brug heraf, farmaceutiske sammensætninger baseret derpå og metoder til fremstilling af dicarboxylsyre bisamid derivater
DK3022174T3 (da)	2019-01-02	Derivater af n-urinstof-substituerede aminosyrer som formylpeptidreceptormodulatorer
DK3054896T3 (da)	2017-11-06	Ledimplantat
DK3615514T3 (da)	2024-02-19	Propionsyre-derivater og deres anvendelsesformål
DK2967936T3 (da)	2021-03-15	Skrå stent
DK3672977T3 (da)	2022-09-26	Boronsyrederivater
HUE042119T2 (hu)	2019-06-28	Aminoészter-származékok
DK2964623T3 (da)	2017-02-13	Substituerede chroman-6-yloxycycloalkaner og deres anvendelse som farmaceutik
BR112013018628A2 (pt)	2017-07-18	derivados da leptina
DK3527192T3 (da)	2021-10-11	Aminosyrederivater og anvendelser deraf
TH1501006859A (th)	2017-07-27	อนุพันธ์ 11-ไฮดรอกซิลและกรดน้ำดีและสารควบคู่กรดอะมิโนของสิ่งนั้นในฐานะ ตัวควบคุมปรับสภาพฟาร์นีซอยด์ x รีเซพเตอร์
DK2763647T3 (da)	2020-03-30	Klæbepræparat til kæbeproteser
TH1501000369A (th)	2016-03-21	องค์ประกอบกำจัดวัชพืชที่ประกอบรวมด้วย 4-อะมิโน-3-คลอโร-5-ฟลูออโร-6-(4-คลอโร-2-ฟลูออโร-3-เมทอกซีฟีนิล) ไพริดีน-2-คาร์บอกซิลิก แอซิด
TH1501001641A (th)	2016-09-06	อนุพันธ์กรดไฮยาลูโรนิกที่ถูกดัดแปลงและการใช้สารนั้น